X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs CIPLA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. CIPLA WOCKHARDT LTD./
CIPLA
 
P/E (TTM) x 16.7 44.1 37.9% View Chart
P/BV x 1.7 3.6 46.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 WOCKHARDT LTD.   CIPLA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-16
CIPLA
Mar-17
WOCKHARDT LTD./
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,000622 321.6%   
Low Rs706458 154.0%   
Sales per share (Unadj.) Rs403.7181.9 222.0%  
Earnings per share (Unadj.) Rs29.512.9 229.0%  
Cash flow per share (Unadj.) Rs42.429.3 144.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs323.4155.7 207.7%  
Shares outstanding (eoy) m110.51804.51 13.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 112.8%   
Avg P/E ratio x45.942.0 109.4%  
P/CF ratio (eoy) x31.918.4 173.3%  
Price / Book Value ratio x4.23.5 120.6%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m149,509434,516 34.4%   
No. of employees `0007.423.0 32.0%   
Total wages/salary Rs m9,44326,338 35.9%   
Avg. sales/employee Rs Th6,048.66,349.1 95.3%   
Avg. wages/employee Rs Th1,280.21,143.0 112.0%   
Avg. net profit/employee Rs Th441.5449.3 98.3%   
INCOME DATA
Net Sales Rs m44,614146,302 30.5%  
Other income Rs m9702,287 42.4%   
Total revenues Rs m45,584148,589 30.7%   
Gross profit Rs m5,03824,758 20.4%  
Depreciation Rs m1,42613,229 10.8%   
Interest Rs m1,0121,594 63.5%   
Profit before tax Rs m3,57012,222 29.2%   
Minority Interest Rs m-650-   
Prior Period Items Rs m6-70 -9.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2551,798 14.2%   
Profit after tax Rs m3,25710,354 31.5%  
Gross profit margin %11.316.9 66.7%  
Effective tax rate %7.114.7 48.5%   
Net profit margin %7.37.1 103.1%  
BALANCE SHEET DATA
Current assets Rs m39,90687,370 45.7%   
Current liabilities Rs m18,42333,081 55.7%   
Net working cap to sales %48.237.1 129.8%  
Current ratio x2.22.6 82.0%  
Inventory Days Days9087 103.7%  
Debtors Days Days9862 157.6%  
Net fixed assets Rs m35,832111,567 32.1%   
Share capital Rs m5531,609 34.3%   
"Free" reserves Rs m30,370123,645 24.6%   
Net worth Rs m35,739125,254 28.5%   
Long term debt Rs m16,54236,454 45.4%   
Total assets Rs m79,522209,532 38.0%  
Interest coverage x4.58.7 52.2%   
Debt to equity ratio x0.50.3 159.0%  
Sales to assets ratio x0.60.7 80.3%   
Return on assets %5.45.7 94.1%  
Return on equity %9.18.3 110.2%  
Return on capital %8.78.5 101.8%  
Exports to sales %11.634.2 33.9%   
Imports to sales %4.58.3 53.5%   
Exports (fob) Rs m5,17750,050 10.3%   
Imports (cif) Rs m1,99012,203 16.3%   
Fx inflow Rs m7,58951,066 14.9%   
Fx outflow Rs m2,87817,678 16.3%   
Net fx Rs m4,71133,388 14.1%   
CASH FLOW
From Operations Rs m71623,824 3.0%  
From Investments Rs m-8,182-13,127 62.3%  
From Financial Activity Rs m2,543-13,239 -19.2%  
Net Cashflow Rs m-4,923-2,478 198.7%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.3 12.2 18.9%  
FIIs % 7.7 23.7 32.5%  
ADR/GDR % 0.1 1.1 9.1%  
Free float % 15.4 26.2 58.8%  
Shareholders   67,757 161,166 42.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Aug 18, 2017 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS